StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a report released on Tuesday. The brokerage issued a sell rating on the medical device company’s stock.
NeuroMetrix Stock Down 0.2 %
Shares of NURO stock opened at $3.70 on Tuesday. The company’s fifty day simple moving average is $3.75 and its 200-day simple moving average is $3.74. The firm has a market cap of $7.44 million, a PE ratio of -0.59 and a beta of 2.30. NeuroMetrix has a 12 month low of $2.70 and a 12 month high of $7.84.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last announced its quarterly earnings data on Wednesday, May 15th. The medical device company reported ($1.67) EPS for the quarter. The business had revenue of $1.09 million during the quarter. NeuroMetrix had a negative return on equity of 39.85% and a negative net margin of 151.51%.
Institutional Trading of NeuroMetrix
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
Further Reading
- Five stocks we like better than NeuroMetrix
- Dividend Capture Strategy: What You Need to Know
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Buy P&G Now, Before It Sets A New All-Time High
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- How to Capture the Benefits of Dividend Increases
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.